

DRUG REGULATORY AUTHORITY OF PAKISTAN

Division of Quality Assurance and Laboratory Testing

RAPID ALERT

DRAP ALERT No: No I/S/08-25-56

CRACKDOWN AGAINST FALSIFIED / SPURIOUS DRUGS

Date: 20th August, 2025

Target Audience:

- Regulatory Field Force of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- Consumers

Problem Statement:

Drug testing Laboratories from Provinces have informed the Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been declared 'Spurious'. The details of reports are as under:

S	# Product Name	Batch No.	Purported Manufacturer	Remarks
1	Brexin Tablet Each tablet contains: Piroxicam-β-Cyclodextrine . (Lyophilized) e.q to Piroxicam20mg	1192087	Purported to be manufactured under license of Chiesi Farmaceutici S.P.A., PARMA- ITALY Marketed by: Chiesi Pharmaceuticals Pvt. Ltd., Lahore.	Drug Testing Laboratory, Rawalpindi Punjab declared the purported drug product as 'Spurious' as defined under clause (i) of subsection (z-b) of Section 3 of the Drugs Act, 1976.
2	Each film coated tablet contains: Azithromycin (as dihydrate)	F18031	Purported to be manufactured under M/s Getz Pharma (Private) Limited. Plot # 01, Sector 25, Korangi Industrial Area, Karachi (DML# 000933).	Drug Testing Laboratory, Rawalpindi declared the purported drug product as 'Spurious' as defined under clause (i) of sub-section (z- b) of Section 3 of the Drugs Act, 1976.
3	Each film coated tablet contains: Amoxicillin (as trihydrate)500 mg. Clavulanic Acid (as potassium salt) 125mg.	7F4W	Purported to be manufactured under M/s GlaxoSmithKline Pakistan Limited, F/268, S.I.T.E. Karachi (DML# 000233).	Drug Testing Laboratory, Multan declared the purported drug product as 'Spurious' as defined under clause (i) & (ii) of sub- section (z-b) of Section 3 of the Drugs Act, 1976.









	Tablet TONOFLEX-P			Drug Testing Laboratory,
			Purported to be manufactured	Rawalpindi declared the
	Each Film Coated Tablet		under M/s Sami Pharmaceuticals	purported drug product as
4.	Contains:	KFM145	(Pvt.) Ltd.	'Spurious' as defined under
	Tramadol HCl 37.5 mg		F-95, S.I.T.E. Karachi	clause (i) & (ii) of sub-
	Paracetamol 325 mg		(DML# 000072).	section (z-b) of Section 3 of
				the Drugs Act, 1976.
	Tablet EFASTON Each film coated tablet contains Dydrogesterone 10 mg	41160	Purported to be manufactured	Drug Testing Laboratory
			under M/s Lahore Chemical &	Rawalpindi declared the
			Pharmaceutical Works (Private)	purported drug product as
5.			Limited.	'Spurious' as defined under
			137- Ferozepur Road, Lahore	clause (i) & (ii) of sub-
			(DML# 000064).	section (z-b) of Section 3 of
			(DML# 000004).	the Drugs Act, 1976.
6.	Capsule Gabica 300 mg	403C27	Purported to be manufactured	Drug testing Laboratory
			under M/s Getz Pharma (Private)	Multan declared the
	Each Capsule contains:		Limited.	purported drug product as
	Pregabalin 300 mg		29-30/27 Korangi Industrial Area,	'Spurious' as defined under
			Karachi	clause (i) & (ii) of sub-
			(DML# 000284)	section (z-b) of Section 3 of
			(recovered from Peddler / Hawker)	the Drugs Act, 1976.
7.	Imcomox Capsule	08	Purported to be manufactured	Drug Testing Laboratory,
			under M/s IMCO Pharmaceutical	Faisalabad declared the
	Each Capsule Contains:		Labs.	purported drug product as
	Amoxycillin trihydrate eq. to		73- Industiral Estate, Hayatabad,	'Spurious' as defined under
	Amoxycillin (U.S.P)		Peshawar.	clause (i) & (ii) of sub-
	500mg		(DML # 000317)	section (z-b) of Section 3 of
				the Drugs Act, 1976.









0		1220	B	D 177
8.	Omnidol NU Tablet	1220	Purported to be manufactured	Drug Water and Food
			under M/s Olive Laboratories.	Testing Laboratory Gilgit
	Each uncoated tablet		Plot No.52-S-6 National Industrial	Baltistan declared the
	contains:		Zone Rawat Rawalpindi. (000524)	purported drug product as
	Paracetamol500mg			under: -
	Caffeine65 mg			For assay of caffeine,
				'Spurious' as defined under
				clause (i) of sub-section (z-
				b) of Section 3 of the Drugs
				Act, 1976 &
				For assay of Paracetamol,
				'Substandard' as defined
				under sub-section (zz) of
				Section 3 of the Drugs Act,
				1976.
9.	CAPSULE CEFSPAN 400	F0580	Purported to be manufactured	Drug Testing Laboratory
	mg		under M/s Barrett Hodgson	Rawalpindi declared the
	9		Pakistan (Pvt) Ltd.	purported drug product as
	Each capsule contains:		, ,	'Spurious' as defined under
	Cefixime400mg		F/423 SITE Karachi. (000457)	clause (i) & (ii) of sub-
	S		` /	section (z-b) of Section 3 of
				the Drugs Act, 1976.
10.	CAPSULE ICON 100 mg	241694	Purported to be manufactured	Drug Testing Laboratory
	Each capsule contains:		under M/s Ferozsons	Rawalpindi declared the
	Itraconazole pellets eq. To		Laboratories Ltd.	purported drug product as
	itraconazole 100 mg		Amangarh Nowshera	'Spurious' as defined under
	2		(DML #000038)	clause (i) & (ii) of sub-
			,	section (z-b) of Section 3 of
				the Drugs Act, 1976.
11.	Tablet NOVIDAT	FIM147	Purported to be manufactured under	Drug Testing Laboratory
	Each film coated tablet		_	Rawalpindi declared the
	contains:		M/s Sami Pharmaceuticals (Pvt)	purported drug product as
	Ciprofloxacin Hydrochloride		Ltd.	'Spurious' as defined under
	eq. to Ciprofloxacin 500mg		F-95 Off Hub River Road, SITE	clause (i) & (ii) of sub-
			Karachi. (DML # 000072)	section (z-b) of Section 3 of
				the Drugs Act, 1976.











"Identification Guide: Original vs Falsified Packaging for Tablet NOVIDAT"



"Identification Guide: Original vs Falsified Packaging for Cefspan"











"Images of the Suspected Falsified Product (Imcomox Capsule)"



Risk Statement:

All the above mentioned purported drug products are confirmed as **falsified/spurious**, as its packaging falsely claims that it was manufactured by a licensed pharmaceutical company—whereas it was not. Laboratory testing has revealed that the product contains **no active pharmaceutical ingredient**, resulting in **complete lack of therapeutic effect**. Such falsification poses a **serious risk to public health**, potentially leading to **treatment failure**, **disease progression**, and even **life-threatening outcomes**, particularly for patients relying on these medications for critical care. The public is strongly advised **not to use these purported drug products** and to report any suspicious or unverified medicines to DRAP immediately.

Action Initiated: -

The Regulatory Field Force of DRAP and Provincial Drug Control Departments has been directed to conduct surveillance activities throughout the supply chain to confiscate the falsified products.









Advice for Healthcare Professionals: -

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using <u>Adverse Event Reporting Form</u> or online through this <u>link</u>. Further information on reporting problems to DRAP is available on this <u>link</u>.

Advice for Consumers:

Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.







